BioSpace2h
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
BioSpace1h
Valerio Shutters U.S. Operations, Cuts Clinical Work Due to ‘Financing Challenges’
Valerio only has cash to last three months, according to the DNA decoy specialist. The news comes less than six months after ...
BioSpace2h
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
BioSpace1h
A Lack of Women in Leadership Is the Biopharma Story That Never Ends
BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...
BioSpace2h
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
BioSpace2h
Women Leaders Decline in Biotech’s Era of ‘Proven Leadership’
Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...
BioSpace9h
Biotech Sisterhood Fills ‘Unmet Need’ for Fellowship Among Women Leaders
At the J.P. Morgan Healthcare Conference, the Biotech Sisterhood assembled in Union Square to showcase the large group of ...
BioSpace21h
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
BioSpace22h
RFK Jr. Passes First Hurdle as Nomination Moves to Full Senate Vote
Senator Bill Cassidy voted with fellow Republicans on the Senate Finance Committee Tuesday morning to move forward the ...
BioSpace4h
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...
BioSpace1d
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
BioSpace23h
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.